ArticlesP53 as a prognostic marker for bladder cancer: a meta-analysis and review
Introduction
A hallmark of bladder cancer is its variable prognosis. About 70% of superficial (Ta and T1) tumours recur, and 10–20% become invasive.1, 2, 3, 4, 5 Tumours that are invasive have a high risk of progression despite radical cystectomy and other treatments.6 Conventional prognostic factors, such as tumour stage, grade, size, and multifocality, do not accurately predict the clinical outcome of many patients with bladder cancer,1, 2, 3, 4, 5 and widespread efforts have been made to identify markers that predict recurrence and progression of the disease, response to treatment, and survival. P53 is the most frequently involved gene in cancer in human beings; its product, P53, has a fundamental role in the control of cell proliferation, apoptosis, and genetic stability.7, 8 Overexpression of P53 in the nucleus, detected by use of immunohistochemical techniques (figure 1), is commonly regarded as a surrogate marker for P53 mutation, and has been the most widely investigated molecular marker in bladder cancer in the past decade.4, 9, 10 The first important report11 which showed that P53 changes were predictive of outcome in patients with bladder cancer undergoing cystectomy was published by Esrig and colleagues in 1994.
We have done a systematic review of papers published in the past decade on changes in P53 and their effects on bladder-cancer prognosis. We aimed to: assess the quality of published studies; summarise the accuracy of changes in P53 in prediction of recurrence, progression, and mortality in patients with bladder cancer; identify factors that could affect the assessment of the prognostic role of changes in P53; and do a meta-analysis of available estimates.
Unlike previous reviews,10, 12, 13, 14, 15 we have included all identified published reports, have assessed potential sources of heterogeneity contributing to conflicting results, and applied quantitative methods to summarise data.
Section snippets
Search strategy and selection criteria
We did a systematic review of original articles published between January, 1993, and July, 2003, in English, Spanish, German, French, Italian, and Portuguese that analysed the prognostic role of P53 overexpression or P53 mutation in patients with bladder cancer. We identified 698 articles from a search of MEDLINE, CancerLit, and EMBASE databases using the keywords “P53” and “bladder neoplasms-in-human”. The number of studies was reduced to 430 by limiting the search with the keywords
Results
Of 168 studies identified, 22 were excluded because they contained duplicate data. 29 articles investigated the same cohort as analysed in an earlier report but assessed different endpoints, focused on different subgroups, or used different P53 antibodies or cut-off points, and were thus included in the review and used for specific analyses only. Webreference lists and webtables 1–6 give further information about these studies.
In all studies reporting a significant result, changes in P53 were
Discussion
Our results showed that estimates of the significance of P53 changes vary substantially between studies. Overall, meta-analysis showed that changes in P53 are weakly predictive of recurrence, progression, and mortality in bladder cancer. However, these findings should be interpreted with caution since only a few studies were eligible for inclusion in the meta-analysis.
P53 has a central role in the cellular response to many types of stress and in the maintenance of genomic stability. This
References (64)
- et al.
Primary superficial bladder cancer risk groups according to progression, mortality and recurrence
J Urol
(2000) - et al.
Multivariate analysis of the prognostic factors of primary superficial bladder cancer
J Urol
(2000) Evaluation and follow-up strategies for superficial bladder cancer
Urol Clin North Am
(2003)- et al.
Prognostic markers in bladder cancer: a contemporary review of the literature
J Urol
(1998) - et al.
Biological markers in superficial bladder tumors and their prognostic significance
Urol Clin North Am
(2000) A critical analysis of the use of p53 as a marker for management of bladder cancer
Urol Clin North Am
(2000)- et al.
The international bladder cancer bank – proposal for a new study concept
Urol Oncol
(2004) - et al.
Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder
J Urol
(1994) - et al.
Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder
J Urol
(1996) - et al.
Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation
J Urol
(1997)
Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy
J Urol
The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates
Hum Pathol
Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours?
Eur J Surg Oncol
Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma
J Urol
Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens
Int J Radiat Oncol Biol Phys
P53 protein expression in transitional cell carcinoma of the bladder - experience of the University of Malaya Medical Centre
Asian J Surg
Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: an alternative to classic prognostic indicators?
Urology
Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder
Urology
5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma
J Urol
A dynamic role of HAUSP in the p53-Mdm2 pathway
Mol Cell
Meta-analysis of the literature or individual patient data; is there a difference?
Lancet
The treatment of bladder cancer—stage by stage. American Urology Association Course Book
What we could do now: molecular pathology of bladder cancer
Mol Pathol
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients
J Clin Oncol
Surfing the p53 network
Nature
p53 and human cancer: the first ten thousand mutations
Adv Cancer Res
p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?
Eur Urol
Accumulation of nuclear p53 and tumor progression in bladder cancer
N Engl J Med
Can p53 staining be used to identify patients with aggressive superficial bladder cancer?
J Pathol
Assessing TP53 status in human tumours to evaluate clinical outcome
Nat Rev Cancer
Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value
Int J Cancer
P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder
Br J Urol
Cited by (280)
Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer
2022, Urologic Oncology: Seminars and Original InvestigationsA glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers
2022, Saudi Journal of Biological SciencesPrognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients
2022, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :Overexpression of Ki-67 has also been correlated with poor survival [12,13,15]. Although their prognostic value was tested in single and multi-center settings, IHC-analyses from multiple centers were done in a single laboratory [8,12]. Mutations in the gene Fibroblast Growth Factor Receptor 3 (FGFR3) have gained interest as a prognostic BC biomarker [13–16].
The emerging role of somatic tumor sequencing in the treatment of urothelial cancer
2021, Asian Journal of UrologyCurrent Perioperative Therapy for Muscle Invasive Bladder Cancer
2021, Hematology/Oncology Clinics of North America
- ‡
These authors contributed equally to the study